Cell Viability Assays Market to grow with a CAGR of 8.80% through 2029
Increasing healthcare infrastructure and a supportive regulatory environment are the major drivers for the Global Cell Viability Assays Market during the forecast period 2025-2029
According to TechSci Research
report, “Cell Viability Assays Market Industry Size, Share, Trends, Competition, Opportunity and
Forecast, 2019-2029”, Global Cell Viability Assays Market has
valued at USD 0.98 billion in 2023 and is anticipated to witness an impressive
growth in the forecast period with a CAGR of 8.80% through 2029. This can be due
to collaborations and partnerships among leading companies with a diverse
approach to merge the expertise of individual companies and to strengthen their
position in the market.
The biotechnology sector's growth significantly influences the Global Cell Viability Assays Market. As the sector expands, there's a heightened demand for diverse tools and technologies supporting research, development, and innovation. Within this ecosystem, cell viability assays play a pivotal role by offering insights into how treatments, substances, and conditions affect cells. In particular, the development of biopharmaceuticals like monoclonal antibodies and recombinant proteins necessitates rigorous assessment of their impact on cell viability to ensure safety and efficacy. Moreover, as biotech firms explore regenerative medicine approaches to address tissue damage, cell viability assays become essential for evaluating the viability and functionality of stem cells and other cell types used in such therapies. Also, the advancement of cell-based therapies such as CAR-T cell therapies relies heavily on understanding the effects of engineered cells on viability and function, with cell viability assays playing a crucial role in ensuring the quality and safety of these therapies.
Browse over XX market data Figures and spread through XX Pages and an in-depth TOC on " Global Cell Viability Assays Market”
Cell viability refers to the presence of living cells, indicating good cell health, which can be altered by chemical or physical agents, as seen in toxic experiments. Cell viability assays (CVAs) are extensively utilized in pharmaceutical and healthcare sectors to gauge cellular responses to pathogens or medications. The Global Cell Viability Assays Market encounters a challenge in aligning with high-content screening (HCS), a potent method combining automated microscopy with image analysis for collecting quantitative data on multiple cellular parameters concurrently. While HCS offers rich insights into cellular behavior, integrating it with cell viability assays presents complexities. CVAs often rely on specific reagents, dyes, or protocols, which may not seamlessly translate to the HCS platform, necessitating adaptation and optimization for accurate and consistent results. HCS enables simultaneous measurement of diverse cellular parameters like morphology, protein expression, and organelle localization. Integrating viability assessment within this multifaceted framework demands careful selection of viability markers that do not disrupt other measurements. Moreover, many HCS applications involve intricate cellular models such as 3D cultures or co-cultures. Adapting cell viability assays to such models while upholding accuracy and reliability poses challenges.
Global Cell Viability
Assays Market segmentation is based on Product, Application, End Use, and
Region
Based on Application, Global Cell
Viability Assays Market is segmented into Drug Discovery and Development, Stem
Cell Research, Diagnostics. Stem cell research investigates unique cells capable of developing into various specialized cell types within the body. These cells, pivotal in tissue and organ development, repair, and regeneration, hold significant promise for medical advancements. Stem cell applications span regenerative medicine, disease modeling, drug discovery, and understanding biological processes. With the ability to differentiate into specialized cells, stem cells offer potential in replacing damaged tissues, addressing conditions like heart disease, spinal cord injuries, and diabetes. Moreover, researchers leverage stem cells to create disease models, enabling the study of disease mechanisms and testing potential treatments.
The Asia Pacific region is poised to experience the most rapid growth in the Global Cell Viability Assays Market. This surge is attributed to escalating research and development endeavors spanning pharmaceuticals, biotechnology, and life sciences. The burgeoning industries drive up demand for cell viability assays, essential for drug discovery, disease research, and various applications. Notably, pharmaceutical and biotechnology firms are expanding their presence in countries such as China, India, Japan, and South Korea within the region. The necessity for robust cell viability assays in drug development amplifies market expansion. Also, enhancements in healthcare infrastructure and investments in medical research propel the demand for advanced tools like cell viability assays. This growth in healthcare capabilities fosters a heightened need for research and diagnostic instruments.
Some of the major companies
operating in the Global Cell Viability Assays Market include:
- Thermo Fisher Scientific, Inc.
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
- Merck KGaA
- PerkinElmer Inc.
- Promega Corporation
- Biotium Inc.
- Creative Bioarra
- Abcam plc
- Charles River Laboratories International, Inc
Download Sample Report
Customers can also request for 10% free customization
on this report
“The Global Cell Viability Assays Market is witnessing
significant growth driven by technological advancements and increased demand
across pharmaceuticals, biotechnology, and research sectors. North America
leads, but Asia Pacific shows promise due to expanding life sciences
investments. Competition is intense, with players investing in R&D and
strategic partnerships. Challenges include regulatory hurdles and costs, but
advancements in precision medicine offer opportunities for growth. Overall, the
market presents lucrative prospects for industry players, researchers, and
healthcare professionals, contributing to healthcare advancements globally.,”
said Mr. Karan Chechi, Research Director of TechSci Research, a
research-based management consulting firm.
“Cell
Viability Assays Market - Global Industry Size, Share,
Trends, Opportunity, and Forecast, 2019-2029 Segmented by Product (Consumables,
Instruments), By Application Type (Drug Discovery and Development, Stem Cell
Research, Diagnostics), By End Use (Biopharmaceuticals and Pharmaceutical
Companies, CROs & CMOs, Academic and Research Institutes, Diagnostic Lab),
and By Region, Competition, 2019-2029F”, has evaluated
the future growth potential of Global Cell Viability Assays Market and provides
statistics & information on market size, structure and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in Global Cell Viability Assays Market.
Contact
TechSci Research LLC
420 Lexington Avenue, Suite 300,
New York, United States- 10170
Tel: +1-332-258-6602
Email: [email protected]
Website: www.techsciresearch.com